



国内版

国际版

Can cyclin-dependent kinase 4/6 inhibitors convert breast can



All

Images

Videos

关闭取词

28,600 Results

Any time ▾

Locally Advanced Breast Cancer - ScienceDirect

<https://www.sciencedirect.com/science/article/pii/B9780323359559000635>

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Author: Ricardo Costa, Nora M Hansen, Willia... Publish Year: 2018

Opportunities and priorities for breast surgical research ...

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(18\)30511-4/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30511-4/fulltext)

Oct 01, 2018 - The 2013 Breast Cancer Campaign gap analysis established breast cancer research priorities without a specific focus on surgical research or the role of surgeons on breast cancer research. This Review aims to identify opportunities and priorities for research in breast surgery to complement the 2013 gap analysis. To identify these goals, research-active breast surgeons met and identified areas ...

Cited by: 4 Author: Ramsey I Cutress, Stuart A McIntosh, Sh...

Publish Year: 2018

Inhibitors of Glioma Growth that Reveal the Tumour to the ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201112>

Receptor tyrosine kinase inhibitors, antireceptor monoclonal antibodies and antisense oligonucleotides, are approaches under investigation to regulate aberrant growth factor signaling pathways in brain tumors. 384 Inhibitors of tyrosine-kinase receptors, that inhibit the Ras signaling pathway, also inhibit the growth of malignant gliomas.

Cited by: 26 Author: Manuel Nieto-Sampedro, Beatriz Valle-Ar...

Publish Year: 2011

Expert Review of Anticancer Therapy via MedWorm.com

<https://medworm.com/journal/expert-review-of-anticancer-therapy.xml>

Presently, fulvestrant is licensed globally as first line endocrine management for advanced breast cancer in post-menopausal women. Early combination trials of fulvestrant and cyclin dependent kinase 4/6 inhibitors have demonstrated good clinical efficacy with improved progression free survi... Fulvestrant for the treatment of advanced breast cancer.

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 52529

Manuscript Type: CASE REPORT

Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report

Palleschi M *et al.* pCR and CDK 4/6i treatment

Michela Palleschi, Roberta Maltoni, Eleonora Barzotti, Elisabetta Melegari, Annalisa Curcio, Lorenzo Cecconetto, Samanta Sarti, Silvia Manunta, Andrea Rocca

Match Overview

1	Internet 69 words doi.org	4%
2	Internet 35 words crawled on 31-Oct-2019 www.wjgnet.com	2%
3	Internet 33 words www.ncbi.nlm.nih.gov	2%
4	Crossref 27 words Giovanna Catania, Paola Malaguti, Simona Gasparro, Francesco Cognetti, Antonello Vidiri, Alessandra Fabi. "Activity ...	2%
5	Internet 15 words crawled on 18-May-2018 link.springer.com	1%
6	Crossref 14 words Zhu, Yaofeng, Shouzheng Chen, Songyu Chen, Jing Song, Fan Chen, Hu Guo, Zhenhua Shang, Yong Wang, Changkuo	1%
7	Internet 13 words crawled on 07-Oct-2019 academic.oup.com	1%
8	Internet 13 words crawled on 18-Mar-2016 www.sabcs.org	1%

Can cyclin-dependent kinase 4/6 inhibitors convert inoperable



ALL

IMAGES

VIDEOS

关闭取词

7,600 Results

Any time ▼

(PDF) Inhibitors targeting CDK4/6, PARP and PI3K in breast ...

https://www.researchgate.net/publication/328835662_Inhibitors_targeting_CDK46_PARP_and...

Recently, three emerging and vital groups of proteins are targeted by SMIs for breast cancer treatment, namely cyclin-dependent kinase 4 and 6 (CDK4/6), poly (adenosine diphosphate-ribose ...

The Emerging Role of Cyclin-Dependent Kinases (CDKs) in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214075>

The CDK4/6 inhibitor palbociclib is FDA-approved for advanced breast cancers, and most literature refers to this substance in breast cancer and most studies investigate the effects of this substance in breast cancer [250,251,252,253]. Only a few studies addressing pancreatic cancer exist.

Cited by: 2

Author: Balbina García-Reyes, Anna-Laura Kretz,...

Publish Year: 2018

Cyclin-dependent kinase inhibitors in brain cancer ...

<https://cdrjournal.com/article/view/3316> ▼

Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc.

The Emerging Role of Cyclin-Dependent Kinases (CDKs) in ...

<https://www.mdpi.com/1422-0067/19/10/3219/htm> ▼

The CDK4/6 inhibitor palbociclib is FDA-approved for advanced breast cancers, and most literature refers to this substance in breast cancer and most studies investigate the effects of this substance in breast cancer [250,251,252,253]. Only a few studies addressing pancreatic cancer exist.

Cited by: 2

Author: Balbina García-Reyes, Anna-Laura Kretz,...

Publish Year: 2018

Endocrine Therapy for Breast Cancer: A Model of Hormonal ...

<https://link.springer.com/article/10.1007/s40487-018-0062-x> ▼

Jul 10, 2018 · These include monoclonal antibodies, tyrosine kinases, mammalian target of rapamycin (mTOR) inhibitors and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The clinical challenge now is to identify the right drug or therapy combination for the right patient for use at the right time.

Cited by: 1

Author: Simon J. Johnston, Kwok-Leung Cheung

Publish Year: 2018



7,590 Results

Any time ▾

Promise of Cyclin-Dependent Kinases 4/6 as Therapeutic ...

<https://www.researchgate.net/publication/280823881...>

Flavopiridol is a **potent cyclin-dependent kinase inhibitor** with preclinical activity against **non-small cell lung cancer** (NSCLC), **inhibiting tumor growth** in vitro and in vivo by cytostatic and ...

Cyclin-dependent kinase inhibitors in brain cancer ...

<https://cdrjournal.com/article/view/3316> ▾

Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions **Cancer Drug Resistance** is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc.

The Emerging Role of Cyclin-Dependent Kinases (CDKs) in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214075>

The CDK4/6 inhibitor **palbociclib** is FDA-approved for advanced **breast cancers**, and most literature refers to this substance in **breast cancer** and most studies investigate the effects of this substance in **breast cancer** [250,251,252,253]. Only a few studies addressing **pancreatic cancer** exist.

Cited by: 2

Author: Balbina García-Reyes, Anna-Laura Kretz,...

Publish Year: 2018

MONARCH 1, a phase II study of abemaciclib, a CDK4 and ...

https://www.researchgate.net/publication/317096285_MONARCH_1_a_phase_II_study_of...

Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors are now the standard of care for **hormone receptor-positive (HR+)**, **HER2-negative (HER-)** metastatic breast cancer (MBC).

Immunotherapy in pancreatic cancer: New hope or mission ...

<https://www.sciencedirect.com/science/article/pii/S0304383519300138>

Cyclin-dependent kinase-4 and 6 are hallmarks of the cancer cell cycle. Specific **inhibitors** that target CDK4 and CDK6 have been used to treat a variety of tumors [93 , 94]. **Palbociclib** was the first CDK4/6 **inhibitor** to illustrate clinical efficacy in ER-positive, HER2-negative advanced **breast cancer** [95].

Cited by: 2

Author: Jiahong Jiang, Huaixiang Zhou, Chao Ni, ...

Publish Year: 2019

Endocrine Therapy for Breast Cancer: A Model of Hormonal ...

<https://link.springer.com/article/10.1007/s40487-018-0062-x> ▾

Jul 10, 2018 · The link between **cyclin-dependent kinase 4/6 inhibitors** and ER activity is